Share Name Share Symbol Market Type Share ISIN Share Description
Eco Animal Health Group Plc LSE:EAH London Ordinary Share GB0032036807 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 205.00 200.00 210.00 205.00 205.00 205.00 230,297 07:44:03
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 74.6 15.2 17.6 11.6 138

Eco Animal Health Share Discussion Threads

Showing 251 to 275 of 1100 messages
Chat Pages: Latest  20  19  18  17  16  15  14  13  12  11  10  9  Older
DateSubjectAuthorDiscuss
27/11/2011
12:25
I have been accumulating shares for over 8 years in anticipation that one day FDA approval for Aivlosin will be granted and the true value of the company will finally be realised with a trade sale.Last week I tried to buy more and could only buy 2500!!!!My patience will one day be rewarded.
ltinvestor
26/11/2011
08:36
Market down 8% in the last two weeks. Virtually all shares have fallen and yet EAH has risen a little. Fingers crossed that this isn't just an anomally and that it signals some good news coming soon.
grahamg8
23/11/2011
07:45
Interims must be due in next couple of weeks. Hopefully they will have continued with a solid performance. Whether or not there will be news of new approvals we'll have to wait and see
audigger
26/10/2011
19:56
Very useful AD cheers!
rathlindri
26/10/2011
09:54
Given how long they have been working with FDA on this and the fact they have not announced any material barrier to securing approval, it would be reasonable to assume this should happen within the next 6 months. What isn't clear to me is whether the delay is just FDA dragging their heels or whether the onus was on Eco to provide/generate more data. Eco haven't been explicitly clear on this point. There is of course a more speculative aspect to Eco relating to possible anti-viral indications of Aivlosin. That combined with FDA vetinary approval would represent a huge upside. The fundamentals look good based only on current business. So my take is that there is plenty of potential upside and a relatively low risk at the curent share price One point ot note though is that the share is very tightly held so in the short-term sharp movement down is possible. Of course DYOR, but I think this Company has excellent prospects
audigger
24/10/2011
11:14
Hello, I've been "lurking" around this share for a few months now after it was tipped on 3i. has the FDA approval in the States been secured yet or is it likeley to be any time soon? Thanks
rathlindri
24/10/2011
09:57
And there canbe little doubt that when that happens they will be looking for an exit strategy at a significant premium to todays share price And its always good to have a divi too!
audigger
23/10/2011
19:19
Yes, lets hope so - sometimes the best investments are the ones with quiet BB's - there is a lot of upside with ECO when it starts to show promise that it can fulfil its business plan.
topvest
23/10/2011
12:45
I am always surprised by the lack of interest in Eco. I believe it increased profits by a whoping 30 percent last year. getting into the USA will be transformational
maxchampagne
21/10/2011
15:59
Lets hope so. Another tick-up today. And only 55 million shares in issue, so with FDA approval the Sp should increase sharply
audigger
20/10/2011
21:49
Must be news on the way. I am hopeful that imminent FDA aproval is the cause for an impressive rise in a poor market.
maxchampagne
20/10/2011
14:01
We appear to be moving north again!
audigger
10/10/2011
16:21
Well my speculation was wrong. On a bit of a drift at the moment so another opportunity to add. Not sure I understand the last RNS. Is it realy a bit of dilution and director sells or simply re-alignment to a new option scheme? Is this respeonsible for the recent drift? I intend to add but have to decide first which of my rather ill portfolio to sell at a loss to get the cash I need to re-invest here.
audigger
25/8/2011
11:25
Lets hope you are correct. I'm sure patience will be rewarded here at some point, so not particularly worried about timing.
topvest
25/8/2011
08:31
Well its pay-day for me today, so think I will buy some more. I working on the theory (and it is only a theory) that Eco will get the FDA approval before the end of FDA's current fiscal year (Sept 30 2011). The VMAC are next scheduled to meet on Sept 12 so my hope is that this is when FDA approval will be granted. All speculation and wishful thinking!
audigger
22/8/2011
09:59
Last trade shows as 1.72. Can't be right?
audigger
22/8/2011
09:57
Strange that this held-up so well during markt chaos but now the market is a tad blue gain this is sliding. Tempted to add, but waiting to see if they slide a little further.
audigger
09/8/2011
16:19
Back to normal, -14p, I should have waited a little longer before adding!
audigger
09/8/2011
15:18
Very strange share price movements. Was 14p down now back to level for the day. Also trades have vanished. Must be an ADVFN glitch.....will have to check Sp on another website
audigger
09/8/2011
12:08
Well these are suddenly cheaper. Have added albeit not many as ain't got much spare cash at the moment. If these get to around 190, then I'll be selling some other shares to buy more as, market chaos aside, these are looking a very attractive prospect once FDA approval is granted
audigger
25/7/2011
08:03
..... and what about the anti viral potential of Aivlosin.Research is continuing in 3 countries on this possibility and a positive outcome will have a major impact on the value of EAH.£6min without this according to Cenkos.What price with it?????
ltinvestor
24/7/2011
13:09
It's almost inevitable IMO that a takeover bid will occur after Aivlosin's full potential becomes apparent in the coming months .
roverite12
23/7/2011
16:15
Interesting...particularly this bit... The broker pointed out that ECO's business model uses third-party distributors who earn up to 50 per cent margins. If the company was acquired by a multinational animal health business, with its own sales force, then the gross profit contribution that could be achieved would be nearly treble that currently produced by ECO.
topvest
23/7/2011
13:51
PROACTIVE article - dated 4pm 22 JULY Shares in ECO Animal Health Group (LON:EAH) were higher by 6.6 per cent at 235 pence each by 1pm today, after the company said its current financial year had started well and reported a strong increase in profit and revenue for the 12 months to 31 March. ECO, which makes environmentally-friendly drugs for livestock, said it had seen positive trends in many of its key markets. Demand from China, its largest market, is strong and it continues to build a presence there and in other important territories. The firm added that it was optimistic that it would soon receive clearance from the US Food and Drug Administration to begin sales of Aivlosin – its flagship drug that is used to provide control of major respiratory and enteric diseases in both pigs and poultry – in that country. Today's results showed that the group increased its turnover for the year to 31 March by 24.4 per cent to £27.1 million (2010: £21.7 million), while its profit – before non-cash charges such as tax, depreciation and amortisation – improved by more than 16 per cent to £6.4 million. On average margins were slightly lower, restrained by currency movements such as last year's strength of sterling against the US dollar as well as by the regional mix of Aivlosin sales and an aggressive local pricing policy to secure large tender business in Brazil. But sales growth in key markets was strong. China, India and Japan posted growth in excess of 40 per cent, while Latin America and South East Asia saw growth exceeding 25 per cent. Sales from ECO's Chinese subsidiary Zhejiang ECO Biok Animal Health Products were greater by nearly 30 per cent in the local currency (and by close to 35 per cent in sterling). ECO said it believes that China remains the market with the greatest potential for its products and it is continuing to seek further opportunities in the country. After China, the US – a market that represents about one third of global demand for animal health drugs – is the next major market that the company is targeting and it expects to launch there soon. The US FDA is still studying ECO's most-recent dossier submission to allow the firm to obtain its first Aivlosin marketing authorisation for a pig claim, while more work is being carried out so that further claims for Aivlosin in the US can be added in the near future. ECO's Japanese subsidiary, ECOpharma, exceeded expectations during its first full year of trading. Following the earthquake in Japan in March 2011, the business's staff and customers remained safe from danger and business returned to normal quickly, ECO said. Europe was broadly flat during the year, reflecting challenging economic conditions in the region. But the firm added that the UK was a notable exception with ECO's new direct-to-market strategy, together with the launch of Aivlosin for 'bulgy eye' – a respiratory disease of pheasants caused by mycoplasma – being well received, delivering sales growth of more than 40 per cent. Cash generation at ECO continued to be strong during the year, with £8.5 million generated compared with £3.3 million in 2010. The firm said that this was achieved thanks to the ongoing implementation of its aggressive stock and debtor management policies ECO has declared a dividend of three pence per share for the year – an increase of 30 per cent over the 2.3 pence it declared for 2010. "ECO Animal Health Group has delivered another strong set of results for the year ended 31 March 2011 and the current year has started well," said Peter Lawrence, ECO's executive chairman. "Overall, ECO is well positioned with an excellent product range, exciting growth opportunities and potentially very important new products in the development phase. The company is poised to accelerate its growth and continue to deliver value to its shareholders." Cenkos Securities, ECO's house broker, believes the group is close to receiving marketing authorisation for Aivlosin in the US. "This represents a huge opportunity for the group although the timeline (which is outside of ECO's control) has lengthened beyond our original expectations," it said. Cenkos forecasts revenues for the current financial year to 31 March 2012 at £30 million, with adjusted pre-tax profits of £3.1 million (translating to earnings per share of 4.2 pence). The broker pointed out that ECO's business model uses third-party distributors who earn up to 50 per cent margins. If the company was acquired by a multinational animal health business, with its own sales force, then the gross profit contribution that could be achieved would be nearly treble that currently produced by ECO. For this reason, Cenkos believes that ECO could be worth 600 pence per share.
roverite12
22/7/2011
12:39
I think the company were asked to provide FDA with additional information and/or clarify questions they had as ECO refer to thier most recent dossier submission "The Food and Drug Administration (FDA) in America is still studying our most recent dossier submission to allow ECO to obtain its first Aivlosin® marketing authorisation for a pig claim. Concurrently, more work is being carried out so that further claims for Aivlosin® in the USA can be added in the near future. Timelines continue to be extended and, as ever, this is completely out of our control". This is all part of the normal proceedings for a new registration but is unfortunately very time consuming.
audigger
Chat Pages: Latest  20  19  18  17  16  15  14  13  12  11  10  9  Older
Your Recent History
LSE
EAH
Eco Animal..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191215 02:02:33